[CAS NO. 934995-87-6] MK-0952
PRODUCTS SPECIFICATIONS [934995-87-6]
DESCRIPTION [934995-87-6]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 483.49 |
| Molecular Formula | C28H22FN3O4 |
| SMILES | O=C([C@H]1[C@H](C2=CC=C(C3=CC=CC(N4C=C(C(NC5CC5)=O)C(C6=C4N=CC=C6)=O)=C3)C=C2F)C1)O |
Summary
IC50 & Target
|
PDE4 0.53 nM (IC 50 ) |
In Vivo
MK-0952 (10 mg/kg) induces malaise in the rat [1] .
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvent & Solubility
DMSO : 50 mg/mL ( 103.41 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.0683 mL | 10.3415 mL | 20.6830 mL |
| 5 mM | 0.4137 mL | 2.0683 mL | 4.1366 mL |
| 10 mM | 0.2068 mL | 1.0341 mL | 2.0683 mL |
References
- [1] Michel Gallant, et al. Discovery of MK-0952, a Selective PDE4 Inhibitor for the Treatment of Long-Term Memory Loss and Mild Cognitive Impairment. Epub 2010 Sep 21.
- [2] Tingting Pan, et al. Dual Functional Cholinesterase and PDE4D Inhibitors for the Treatment of Alzheimer's Disease: Design, Synthesis and Evaluation of tacrine-pyrazolo[3,4-b]pyridine Hybrids. Behav Brain Res. 2016 Apr 15;303:26-33.